IV 冲洗注射器全球市场-2022-2029

市场动态

IV 闪光注射器的创新有望推动市场增长。

双腔注射器是药物和设备组合产品，旨在促进轻鬆重构和预定义数量的药物给药。当今市场上的许多多流体注射器并不是很受欢迎，因为它们经常注射两种流体，一种已经预先填充，另一种需要填充药物的空腔。然而，没有一种注射器可以同时给药通常的药物溶液和随后的导管清洁，并且它正在变得普遍。新开发的两室注射器填补了这一市场空白，可以同时填充和供应化学溶液和清洁溶液。此外，这种注射器的使用使护士在输液过程中更容易进行冲洗，预计将具有缩短准备和给药时间、减少导管调整次数以及减少与 PIVC 相关的问题等效果。因此，从上述陈述来看，预计将在预测期内推动市场。

与 IV 冲洗注射器相关的并发症预计会阻碍市场增长。

当一个或多个气泡进入动脉或静脉并限制血流时，就会发生空气栓塞。注射器或滴管可能会无意中将空气注入静脉。大多数空气栓塞是良性的，很少或没有症状。空气栓塞通常会自行消退而不会产生不良影响。然而，空气栓塞非常罕见，很少影响大脑、心臟或肺部。如果发生空气栓塞，可能会导致心脏病发作、中风和呼吸衰竭。

此外，氯化钠清洁剂的两个更严重的副作用是体液过多和过敏反应。虽然相对罕见，但两者都可能致命并增加清洗注射器的召回率。因此，从上述陈述来看，预计市场在预测期内将受到阻碍。

行业分析

IV Flash Syringe Market 根据供应链分析、价格分析等各种行业因素对市场进行深入分析。

COVID-19 影响分析

COVID-19 大流行对医疗保健系统和市场产生了积极影响。全球 COVID-19 大流行对药剂师和护士等医护人员的心理、情感和身体造成了严重影响。此外，临床工作人员必须穿戴额外的个人防护装备 (PPE)，由于病毒的传染性，这可能会限制运动范围和反应时间。这增加了药物製备和给药错误的可能性。使用即用型 (RTA) 是减轻医生负担和尽量减少复杂药物製备程序的策略之一。例如，预充式註射器和其他 RTA 项目可以大大提高生产力，同时最大限度地减少错误和患者受伤的机会。

与此同时，自 2022 年 3 月 21 日起，美国食品药品监督管理局 (FDA) 已确定全国短缺含有 0.9% 氯化钠（盐水）的预装静脉 (IV) 锁定/冲洗注射器。我知道这一点.由于 COVID-19 公共卫生紧急情况期间需求增加以及供应商供应链随后出现的困难，包括一些预装盐水锁/冲洗注射器的永久停产，预装 0.9% 氯化钠静脉锁/冲洗注射器的注射器快用完了。因此，从上述陈述来看，预计市场在预测期内将蓬勃发展。

本报告提供对全球 IV 闪光注射器市场约 45 多个市场数据表、40 多个图表和 160 页的访问。

内容

第一章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

• 市场影响因素
  • 驱动程序
    • IV 闪光注射器的创新有望推动市场增长。
  • 限制因素
    • 预计与 IV 闪光注射器相关的并发症会阻碍市场增长。
  • 市场机会
  • 影响分析

第五章行业分析

• 供应链分析
• 定价分析

第 6 章 COVID-19 分析

• COVID-19 的市场分析
  • COVID-19 之前的市场情景
  • COVID-19 的当前市场情景
  • COVID-19 后或未来情景
• COVID-19 期间的价格动态
• 供需范围
• 大流行期间与市场相关的政府举措
• 製造商的战略举措
• 总结

第 7 章按类型

• 生理盐水滴管
• 肝素 IV 冲洗注射器

第 8 章最终用户

• 医院
• 诊所
• 门诊手术中心
• 其他

第 9 章按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第 10 章竞争格局

• 主要发展和战略
• 公司份额分析
• 产品基准
• 值得关注的重点公司列表

第 11 章公司简介

• B.Braun Melsungen AG
  • 公司简介
  • 产品组合和描述
  • 主要亮点
  • 财务摘要
• R. A. Caldwell Co. Inc.
• Becton, Dickinson and Company
• Cardinal Health
• Nipro Corporation
• Aquabiliti
• Medline Industries, LP
• Medefil, Inc.
• Polymedicure
• SteriCare Solutions

第 12 章 IV 冲洗注射器全球市场数据M

Market Overview

IV Flush Syringe Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.7 % during the forecast period (2022-2029).

IV flush syringes are common medical devices used to clear intravenous lines. Saline flushes are generally safe and well tolerated by patients when administered properly. Millions of patients use it daily to clean intravenous lines. This makes it more likely that medications will be completely absorbed, won't mix inside the tube, and that blood there won't clot. Saline IV flush syringes and heparin IV flush syringes are the two types of IV flush syringes.

Market Dynamics

Innovation in the IV flush syringes is expected to drive market growth.

Double-chamber syringes have been created as a medicine and device combo product to make it easier to reconstitute and administer pharmaceuticals in predefined amounts. Since they frequently call for the delivery of two fluids, one flush solution that has already been prefilled and an empty chamber that needs to be filled with medication, many of the currently available syringes sold for the administration of multiple fluids have not been well welcomed. However, no syringe that enables filling both chambers simultaneously, one for ordinary medication administration and the other for a subsequent catheter flush, has acquired broad popularity. A double-chamber syringe is created to cover this market gap and allow for the filling and delivery of medication and flush solution. Moreover, the novel syringe is expected to make it easier for nurses to implement best clinical practices during intravenous medication administration, such as flushing, cutting down on preparation and administration time, reducing the number of catheter adjustments, and lowering PIVC-related problems. Thus, from the above statements, the market is expected to drive in the forecast period.

Complications associated with IV Flush Syringe are expected to hamper the market growth.

An air embolism develops when one or more air bubbles enter an artery or vein and restrict blood flow. A syringe or IV can inadvertently inject air into a vein. The majority of air embolisms are benign, producing very subtle symptoms or none at all. These typically go away on their own without having any negative effects. However, air embolisms are extremely rare and rarely affect the brain, heart, or lungs. If they do, a heart attack, stroke, or respiratory failure could result.

Moreover, fluid overload and an allergic reaction are two more severe side effects of a sodium chloride flush. Despite being relatively uncommon, both can be fatal and increase recalls of flush syringes. Thus, from the above statements, the market is expected to get hampered in the forecast period.

Industry Analysis

The IV flush syringe market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has positively impacted healthcare systems and the market. Health care professionals, such as pharmacists and nurses, have experienced significant psychological, emotional, and physical effects due to the global COVID-19 pandemic. Moreover, clinical workers must wear additional personal protective equipment (PPE) that might restrict their range of motion and reaction time due to the virus's contagious nature. This raises the likelihood of mistakes occurring when medications are prepared and administered. Utilizing ready-to-administer (RTA) medications is one strategy to ease physicians' workload and minimize complicated drug preparation steps. Prefilled syringes and other RTA items, for instance, can significantly improve productivity while minimizing mistakes and possible patient injury.

In contrast, as of March 21, 2022, the U.S. Food and Drug Administration (FDA) is aware that there are shortages of prefilled intravenous (IV) lock/flush syringes that contain 0.9 percent sodium chloride (saline) in the country. Due to a rise in demand during the COVID-19 public health emergency and subsequent vendor supply chain difficulties, including the permanent discontinuation of some prefilled saline lock/flush syringes, there is a shortage of prefilled 0.9 percent sodium chloride IV lock/flush syringes. Thus, from the above statements, the market is expected to boost in the forecast period.

Segment Analysis

Saline IV Flush Syringe segment is expected to hold the largest market share in IV Flush Syringe market

The saline IV flush syringe segment is expected to dominate in 2021. The segment benefits because the hazards of microbial contamination that arise when doses are drawn up at the ward level are eliminated by the use of prefilled saline syringes. Additionally, the chance of incorrect selection is decreased by the completely labeled nature of prefilled syringes. The time saved by nurses is another important issue. Ad hoc preparation of intravenous dosages incurs costs (including disposables and nurse time) that are frequently disregarded but can pile up in a busy ward. According to one study, using prefilled syringes reduced nursing time by 42% compared to using traditional injection systems.

Further, under the NPSA recommendation, Northampton General Hospital introduced prefilled saline syringes early this year as a part of a broader push to reduce the use of heparin flushes. The NPSA Alert 20, Promoting Safer Use of Injectable Medicines, served as the starting point and contained several action items and suggested actions to increase the safety of injectable medications. Therefore, it has increased the demand for saline IV flush syringes. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global IV flush syringe market

In 2021, North America accounted for the highest revenue share. The increasing inpatient admissions for chronic diseases, rising surgical procedures, the high adoption of the IV flush syringe, well-established infrastructure and product launches and acquisitions by the region's key market players are some factors the market is expected to boost in the forecast period. For instance, heart disease is the leading cause of death for both sexes and members of most racial and ethnic groups in the United States. Cardiovascular disease claims one life in the United States every 34 seconds. In the United States, heart disease claimed the lives of almost 697,000 people in 2020, accounting for 1 in 5 fatalities. Patients with heart disease who experience an aggravation must be admitted to the hospital and given special care. The strong demand for these syringes is expected to be influenced by this issue.

Moreover, BD (Becton, Dickinson and Company) announced in October 2021 that it had strengthened the US government's access to safe injection devices by boosting production. The public-private cooperation between BD and the Assistant Secretary for Preparedness and Response at the Department of Health and Human Services (HHS) created the new syringe and needle manufacturing lines (ASPR). Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the IV flush syringe market are B. Braun Melsungen AG, R. A. Caldwell Co. Inc., Becton, Dickinson and Company, Cardinal Health, Nipro Corporation, Aquabiliti, Medline Industries, LP, Medefil, Inc., Polymedicure, SteriCare Solutions.

B. Braun Melsungen AG:

Overview:

B. Braun is a German manufacturer of medical and pharmaceutical devices. The B. Braun product line includes 5,000 items, 95 percent of which are manufactured by the company. The company's product portfolio includes infusion, nutrition, pain therapy products, infusion pumps and systems, surgical instruments, suture materials, hip and knee implants, dialysis equipment and accessories, ostomy, disinfection, and wound care products. The company operates its business through five divisions: hospital care, Aesculap, B. Braun Avitum, out-patient market (OPM) and other sales. B. Braun has a presence in 64 countries and develops products in 18 therapy fields of the healthcare industry.

Product Portfolio:

Omniflush with SwabCap: A standard saline intravenous flush syringe with an integrated SwabCap is called an Omniflush with SwabCap. A SwabCap is a luer access valve cap with a 70% isopropyl alcohol disinfection concentration. For the user's convenience, they are incorporated together. The purpose of SwabCap is to serve as a cover for swab-able Luer access valves, shielding them from potential contamination. The SwabCap is a cleaning disinfectant before line access and a physical barrier to contamination between line accesses. SwabCap will disinfect the valve thirty (30) seconds after application and maintains a disinfected valve surface for up to seven (7) days if not removed.

The global IV flush syringe market report would provide an access to an approx. 45+market data table, 40+figures and 160pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Innovation in the IV flush syringes is expected to drive market growth.
  • 4.1.2. Restraints:
    • 4.1.2.1. Complications associated with IV Flush Syringe are expected to hamper the market growth.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Supply Chain Analysis
• 5.2. Pricing Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type Segment
• 7.2. Saline IV Flush Syringe*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Heparin IV Flush Syringe

8. By End user

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 8.1.2. Market Attractiveness Index, By End user Segment
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Clinics
• 8.4. Ambulatory Surgical Center
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

10. Competitive Landscape

• 10.1. Key Developments and Strategies
• 10.2. Company Share Analysis
• 10.3. Product Benchmarking
• 10.4. List of Key Companies to Watch

11. Company Profiles

• 11.1. B. Braun Melsungen AG*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. R. A. Caldwell Co. Inc.
• 11.3. Becton, Dickinson and Company
• 11.4. Cardinal Health
• 11.5. Nipro Corporation
• 11.6. Aquabiliti
• 11.7. Medline Industries, LP
• 11.8. Medefil, Inc.
• 11.9. Polymedicure
• 11.10. SteriCare Solutions

LIST NOT EXHAUSTIVE

12. Global IV Flush Syringe Market - DataM

• 12.1. Appendix
• 12.2. About Us and Applications
• 12.3. Contact Us